Results 161 to 170 of about 4,079,288 (357)
Reversible disaggregation of the cytosol-estrogen binding protein of uterine cytosol. [PDF]
, 1968 Stanley G. Korenman, B. Ramanath Rao
openalex +1 more source
Molecular Oncology, EarlyView.This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau +9 more
wiley +1 more source
ORGANIC ANION-BINDING PROTEIN IN RAT LIVER: DRUG INDUCTION AND ITS PHYSIOLOGIC CONSEQUENCE [PDF]
, 1969 Humberto Reyes +3 more
openalex +1 more source
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
Molecular Oncology, EarlyView.We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp +13 more
wiley +1 more source
Predicting Protein Binding of Drugs Using Abraham Parameters: Effect of Ionization
Journal of Mazandaran University of Medical Sciences, 2019 Background and purpose: Protein binding (PB) is an important pharmacokinetic parameter in drug discovery and development. In past years Abraham parameters were used to predict some physicochemical and pharmacokinetic properties of drugs.
Shadi Shayanfar, Ali Shayanfar
doaj
TRANSCORTIN: A CORTICOSTEROID-BINDING PROTEIN OF PLASMA. III. THE EFFECTS OF VARIOUS STEROIDS *† [PDF]
, 1960 Avery A. Sandberg +2 more
openalex +1 more source
Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source
Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma
Molecular Oncology, EarlyView.The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias +12 more
wiley +1 more source
Editorial: Machine learning in computer-aided drug design
Frontiers in Molecular BiosciencesOgnjen Perišić +2 more
doaj +1 more source